PTC Therapeutics (PTCT) News Today $50.20 -0.23 (-0.46%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$50.20 0.00 (0.00%) As of 06/20/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PTCT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Truist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug LaunchesJune 20 at 10:27 AM | msn.comPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 19 at 4:30 PM | prnewswire.comPTC Therapeutics (NASDAQ:PTCT) Now Covered by Analysts at Truist FinancialJune 19 at 1:43 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 18 at 12:35 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 17, 2025 | prnewswire.comTruist Financial Begins Coverage on PTC Therapeutics (NASDAQ:PTCT)Truist Financial initiated coverage on shares of PTC Therapeutics in a research note on Tuesday. They set a "buy" rating and a $80.00 price target on the stock.June 17, 2025 | marketbeat.comPTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law FirmJune 16, 2025 | businesswire.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Stake Lowered by Assenagon Asset Management S.A.Assenagon Asset Management S.A. cut its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 23.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 337,960 shares of the biopharmaceutical company's stockJune 14, 2025 | marketbeat.comPallas Capital Advisors LLC Makes New $353,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)Pallas Capital Advisors LLC purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,925 shares of the biopharmacJune 13, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by GAMMA Investing LLCGAMMA Investing LLC raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 9,393.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,514 shares of the biopharmaceutical coJune 13, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 12, 2025 | prnewswire.comHarbor Capital Advisors Inc. Cuts Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Harbor Capital Advisors Inc. lowered its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 22.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 40,725 shares of the biopharmaceutical comJune 12, 2025 | marketbeat.comAnalysts Issue Forecasts for PTCT FY2026 EarningsJune 12, 2025 | americanbankingnews.comBrokers Offer Predictions for PTCT FY2026 EarningsPTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for PTC Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska expects that the biopharmaceutical company will post eJune 10, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 7, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 6, 2025 | globenewswire.comWilliam Blair Cuts Earnings Estimates for PTC TherapeuticsPTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Stock analysts at William Blair decreased their Q2 2025 earnings per share estimates for shares of PTC Therapeutics in a research note issued on Tuesday, June 3rd. William Blair analyst S. Corwin now forecasts that the biopharmaceutical companyJune 6, 2025 | marketbeat.comPublic Employees Retirement System of Ohio Sells 17,657 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Public Employees Retirement System of Ohio reduced its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 76.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,542 shares of the biopharmaceutical companJune 6, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 2, 2025 | globenewswire.comUniversal Beteiligungs und Servicegesellschaft mbH Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 108,345 shares of the biopharmaceutical company's stock, valued atJune 2, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 19.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 160,251 shares of tJune 2, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 1, 2025 | prnewswire.comMackenzie Financial Corp Increases Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Mackenzie Financial Corp boosted its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 132.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 22,776 shares of the biopharmaceutical cJune 1, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Ameriprise Financial Inc.Ameriprise Financial Inc. decreased its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 37.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 42,934 shares of the biopharmaceutical companJune 1, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of "Moderate Buy" by BrokeragesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the fourteen brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating, eigMay 29, 2025 | marketbeat.comWells Fargo & Company Forecasts Strong Price Appreciation for PTC Therapeutics (NASDAQ:PTCT) StockWells Fargo & Company raised their price objective on shares of PTC Therapeutics from $68.00 to $74.00 and gave the company an "overweight" rating in a research report on Tuesday.May 28, 2025 | marketbeat.comToronto Dominion Bank Invests $148.36 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT)Toronto Dominion Bank purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 3,286,729 shares of the biopharmaceutical company's stock, valuedMay 27, 2025 | marketbeat.comTwo Sigma Investments LP Has $7.83 Million Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Two Sigma Investments LP decreased its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 45.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 173,352 shares of the biopharmaceutical company's stockMay 27, 2025 | marketbeat.comQuantinno Capital Management LP Makes New $436,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)Quantinno Capital Management LP acquired a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 9,656 shares of the biopharmaceutical company's stock, valued at approximatelyMay 27, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTMay 26, 2025 | prnewswire.comWoodline Partners LP Buys New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Woodline Partners LP purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 155,883 shares of the biopharmaceutical company's stock, vaMay 26, 2025 | marketbeat.comState of Wyoming Makes New Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)State of Wyoming purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,776 shares of the biopharmaceutical company's stock,May 26, 2025 | marketbeat.comBNP Paribas Financial Markets Has $465,000 Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)BNP Paribas Financial Markets reduced its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 85.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,292 shares of the biopharmaceutical cMay 26, 2025 | marketbeat.comProShare Advisors LLC Buys 6,164 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)ProShare Advisors LLC raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 32.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,102 shares of tMay 25, 2025 | marketbeat.comMillennium Management LLC Purchases 89,959 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Millennium Management LLC boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 41.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 309,423 shares of the biopharmaceutical cMay 25, 2025 | marketbeat.comBank of America Corp DE Sells 58,187 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Bank of America Corp DE reduced its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 18.5% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 256,536 shares of the biopharmaceutical company's stock afterMay 25, 2025 | marketbeat.comVoloridge Investment Management LLC Sells 92,168 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Voloridge Investment Management LLC decreased its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 14.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 568,364 shares of the biopharmaceMay 24, 2025 | marketbeat.comTwo Sigma Advisers LP Reduces Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Two Sigma Advisers LP trimmed its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 16.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 360,442 shares of the biopharmaceutical comMay 24, 2025 | marketbeat.comThose who invested in PTC Therapeutics (NASDAQ:PTCT) three years ago are up 51%May 22, 2025 | finance.yahoo.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Position Raised by Nuveen Asset Management LLCNuveen Asset Management LLC lifted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 34.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,077,794 shares of the biopharmaceuticalMay 22, 2025 | marketbeat.comDeutsche Bank AG Boosts Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)Deutsche Bank AG boosted its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 92.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 94,378 shares of the biopharmaceutical companyMay 22, 2025 | marketbeat.comRafferty Asset Management LLC Sells 23,231 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Rafferty Asset Management LLC trimmed its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 22.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 78,032 shares of the biopharmaceutical compaMay 21, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTMay 20, 2025 | prnewswire.comPTC Therapeutics, Inc. (NASDAQ:PTCT) VP Sells $40,635.66 in StockMay 20, 2025 | insidertrades.comLazard Asset Management LLC Acquires 34,069 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Lazard Asset Management LLC lifted its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 294.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 45,647 shares of the biopharmaceutical compMay 20, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTMay 18, 2025 | globenewswire.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Holdings Boosted by Point72 Asset Management L.P.Point72 Asset Management L.P. boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 150.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,443,362 shares of the biopharmaceutical company'sMay 18, 2025 | marketbeat.comPoint72 Hong Kong Ltd Purchases 21,034 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Point72 Hong Kong Ltd boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 184.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 32,436 shares of the biopharmaceutical company's stMay 18, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Rating Lowered to Buy at StockNews.comStockNews.com downgraded shares of PTC Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday.May 18, 2025 | marketbeat.com14,998 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Acquired by Graham Capital Management L.P.Graham Capital Management L.P. bought a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 14,998 shares of the biopharmaceutical company's stock,May 17, 2025 | marketbeat.com Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address PTCT Media Mentions By Week PTCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTCT News Sentiment▼0.360.65▲Average Medical News Sentiment PTCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTCT Articles This Week▼88▲PTCT Articles Average Week Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SMMT News GMAB News ITCI News RDY News ASND News VTRS News QGEN News MRNA News BPMC News BBIO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTCT) was last updated on 6/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTCT Stock Free PTCT Stock Alerts